Prävention und Therapie der Retinopathia praematurorum

Einleitung

Nach wie vor zählt die Frühgeborenenretinopathie (Retinopathia praematurorum, RPM) zu den häufigsten Erblindungsursachen in den Industrienationen im Kindesalter. Die neonatologischen Fortschritte haben in den letzten Jahren und Jahrzehnten das Überleben immer unreiferer Frühgeborener ermöglicht. Gleichzeitig hat unser Wissen um Zusammenhänge zwischen der Entwicklung und Progression einer RPM auf der einen und systemischen Parametern auf der anderen Seite enorme Fortschritte gemacht. Gemeinsam sind daher Neonatologen und Augenärzte vor die Aufgabe gestellt, die Prophylaxe und Therapie der RPM mithilfe dieses neu hinzugewonnenen Wissens so gut wie möglich zu optimieren, damit die verbesserten Überlebenschancen nicht mit einem erhöhten Anteil an sehbehinderten Kindern einhergehen.

Der folgende Artikel soll entsprechend dem jetzigen Stand der Literatur einen Überblick sowohl über Möglichkeiten der Prophylaxe der RPM als auch über aktuelle Überlegungen zur Therapie geben.

• Literatur

• 1 Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000; 41: 1217-1228
• 2 Löfqvist C, Anderson E, Sigurdsson J et al. Longitudinal postnatal weight and Insulin-like Growth Factor I measurements in prediction of Retinopathy of Prematurity. Arch Ophthalmol 2006; 124: 1711-1718
• 3 Smith LE. Through the eyes of a child: understanding retinopathy through ROP- the Friedenwald lecture. Invest Ophthalmol Vis Sci 2008; 49: 5177-5182
• 4 Sonmez K, Drenser K, Capone A et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008; 115: 1065-1070
• 5 Hellström A, Ley D, Hansen-Pupp I et al. New insights into the development of retinopathy of prematurity – importance of early weight gain. Acta Paediatr 2010; 99: 502-508
• 6 Smith LE, Shen W, Perruzzi C et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularisation by insulin-like growth factor-1 receptor. Nat Med 1999; 5: 1390-1395
• 7 Chen YH, Lien RI, Tsai S et al. Natural history of retinopathy of prematurity: two-year outcomes of a prospective study. Retina 2015; 35: 141-148
• 8 Lundgren P, Kistner A, Andersson EM et al. Low birth weight is a risk factor for severe retinopathy of prematurity depending on gestational age. PLoS One 2014; 9: e109460
• 9 Yau GS, Lee JW, Tam VT et al. Risk factors for retinopathy of prematurity in extremely preterm chinese infants. Medicine (Baltimore) 2014; 93: e314
• 10 Saugstad OD, Aune D. Optimal Oxygenation of Extremely Low Birth Weight Infants: A Meta-Analysis and Systematic Review of the Oxygen Saturation Target Studies. Neonatology 2014; 105: 55-63
• 11 Hartnett ME, Lane RH. Effects of oxygen on the development and severity of retinopathy of prematurity. J AAPOS 2013; 17: 229-234
• 12 Di Fiore JM, Bloom JN, Orge F et al. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr 2010; 157: 69-73
• 13 Kaufman DA, Zanelli SA, Gurka MJ et al. Time outside targeted oxygen saturation range and retinopathy of prematurity. Early Hum Dev 2014; 90: 35-40
• 14 Bizzarro MJ, Li FY, Katz K et al. Temporal quantification of oxygen saturation ranges: an effort to reduce hyperoxia in the neonatal intensive care unit. J Perinatol 2014; 34: 33-38
• 15 McColm JR, Cunningham S, Wade J et al. Hypoxic oxygen fluctuations produce less severe retinopathy than hyperoxic fluctuations in a rat model of retinopathy of prematurity. Pediatr Res 2004; 55: 107-113
• 16 Wu C, Löfquist C, Smith LEH et al. for the WINROP Consortium Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants. Arch Ophthalmol 2012; 130: 992-999
• 17 Flückiger S, Bucher HU, Hellström A et al. The early postnatal weight gain as a predictor of retinopathy of prematurity. Klin MonBl Augenheilkd 2011; 228: 306-310
• 18 Binenbaum G. Algorithms for the prediction of retinopathy of prematurity based on postnatal weight gain. Clin Perinatol 2013; 40: 261-270
• 19 Sjöström SE, Lundgren P, Öhlund I et al. Low energy intake during the first 4 weeks of life increases the risk for severe retinopathy of prematurity in extremely preterm infants. Arch Dis Child Fetal Neonatol Ed 2015; DOI: 10.1136/archdischild-2014-306816
• 20 Ertl T, Gyarmati J, Gaál V et al. Relationship between hyperglycemia and retinopathy of prematurity in very low birth weight infants. Biol Neonate 2006; 89: 56-59
• 21 Garg R, Agthe AG, Donohue PK et al. Hyperglycemia and retinopathy of prematurity in very low birth weight infants. J Perinatol 2003; 23: 186-194
• 22 Kaempf JW, Kaempf AJ, Wu Y et al. Hyperglycemia, insulin and slower growth velocity may increase the risk of retinopathy of prematurity. J Perinatol 2011; 31: 251-257
• 23 Raghuveer TS, Bloom BT. A paradigm shift in the prevention of retinopathy of prematurity. Neonatology 2011; 100: 116-129
• 24 Dani C, Poggi C, Bresci C et al. Early fresh-frozen plasma transfusion decreases the risk of retinopathy of prematurity. Transfusion 2014; 54: 1002-1007
• 25 Rivera JC, Sapieha P, Joyal JS et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology 2011; 100: 343-353
• 26 Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol 2009; 24: 77-81
• 27 Kandasamy Y, Kumar P, Hartley L. The effect of erythropoetin on the severity of retinopathy of prematurity. Eye (Lond) 2014; 28: 814-818
• 28 Ohlsson A, Aher SM. Early erythropoetin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014; 26: 4
• 29 Aher SM, Ohlsson A. Late erythropoetin for preventing red blood cell transfusion n preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014; 23: 4
• 30 Weintraub Z, Carmi N, Elouti H et al. The association between stage 3 or higher retinopathy of prematurity and other disorders of prematurity. Can J Ophthalmol 2011; 46: 419-414
• 31 Hübler A, Knote K, Kauf E et al. Does insulin-like growth factor 1 contribute in red blood cell transfusions to the pathogenesis of retinopathy of prematurity during retinal neovascularization?. Biol Neonate 2006; 89: 92-98
• 32 Liu PM, Fang PC, Huang CB et al. Risk factors of retinopathy of prematurity in premature infants weighing less than 1600 g. Am J Perinatol 2005; 22: 115-120
• 33 Casini G, Dal monteM, Fornaciari I et al. The Beta-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Progr Retin Eye Res 2014; 42: 103-129
• 34 Filippi L, Cavallaro G, Bagnoli P et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr 2013; 163: 1570-1577
• 35 Dal Monte M, Casini G, La Marca G et al. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp Exe Res 2013; 111: 27-35
• 36 Chen J, Joyal JS, Hatton CJ et al. Propranolol inhibition of betaadrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2012; 53: 2968-2977
• 37 Hard AL, Hellström A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr 2011; 100: 1063-1065
• 38 Jandeck C, Kellner U, Lorenz B et al. Arbeitsgruppe der Retinologischen Gesellschaft zur Erstellung der Letilinie zur augenärztlichen Screening-Untersuchung von Frühgeborenen. Augenärztliche Screening-Untersuchung von Frühgeborenen. Klin Monatsbl Augenheilkd 2008; 225: 123-130
• 39 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988; 106: 471-479
• 40 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Final results. 15-year outcomes following threshold retinopathy. Arch Ophthalmol 2005; 123: 311-318
• 41 White JE, Repka MX. Randomized comparison of diode laser photocoagulation verus cryotherapy for threshold retinopathy of prematurity: 3-year outcome. J Pediatr Ophthalmol Strabismus 1997; 34: 83-87
• 42 Paysse EA, Lindsey JL, Coats DK et al. Therapeutic outcomes of cryotherapy versus transpupillary diode laser photocoagulation for threshold retinopathy of prematurity. J AAPOS 1999; 3: 234-240
• 43 Connolly BP, Ng EY, McNamara JA et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology 2002; 109: 936-941
• 44 Jandeck C, Kellner U, Heimann H et al. Koagulatioinstherapie der Frühgeborenenretinopathie: Vergleich der anatomischen und funktionellen Ergebnisse nach Laser- oder Kryokoagulation. Ophthalmologe 2005; 102: 33-38
• 45 Ng EY, Connolly BP, McNamara JA et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 2002; 109: 928-935
• 46 Capone Jr A, Diaz-Rohena R, Sternberg Jr P et al. Diode-laser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol 1993; 116: 444-450
• 47 The Laser ROP Study Group. Laser therapy for retinopathy of prematurity. Arch Ophthalmol 1994; 12: 154-156
• 48 Axer-Siegel R, Maharshak I, Snir M et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina 2008; 28: 839-846
• 49 Banach MJ, Ferrone PJ, Trese MT. A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 2000; 107: 324-327
• 50 Fallaha N, Lynn MJ, Aaberg Jr TM et al. Clinical outcome of confluent laser photoablation for retinopathy of prematurity. J AAPOS 2002; 6: 81-85
• 51 The Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684-1696
• 52 Mintz-Hittner HA, Kennedy KA, Chuang AZ et al. Efficacy of intravitreal Bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-615
• 53 Mintz-Hittner HA, Kuffel Jr RR. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008; 28: 831-838
• 54 Kusaka S, Shima C, Wada K et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008; 92: 1450-1455
• 55 Lalwani GA, Berrocal AM, Murray TG et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008; 28: 13-18
• 56 Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28: 19-25
• 57 Oberacher-Velten I, Helbig H. VEGF antibodies as therapy for retinopathy of prematurity. Klin Monbl Augenheilkd 2010; 227: 694-700
• 58 Arevalo JF, Maia M, Flynn Jr HW et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213-216
• 59 Hard A-L, Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review. Acta Paediatr 2011; 100: 1523-1527
• 60 Kong L, Bhatt AR, Demny AB et al. Pharmacokinetics of Bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 2015; 56: 956-961
• 61 Kodjikian L, Souied EH, Mimoun G et al. Ranibizumab versus Bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomizd trial. Ophthalmology 2013; 120: 2300-2309
• 62 Castellanos MA, Schwartz S, Garcia-Aguirre G et al. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 2013; 97: 816-819
• 63 Lin CJ, Chen SN, Hwang JF. Intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight infant with rush type retinopathy of prematurity. Oman J Ophthalmol 2012; 5: 184-186
• 64 Chen SN, Lian I, Hwang YC et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina 2015; 35: 667-674
• 65 Barth T, Hufendiek K, Helbig H et al. Laser treatment or intravitreal VEGF inhibition for aggressive posterior retinopathy of prematurity?. Ophthalmologe 2015; [epub ahead of print]
• 66 Stellungnahme von DOG, Retinologischer Gesellschaft und BVA zum Einsatz von Bevacizumab in der Therapie der Frühgeborenenretinopathie. 20. 12. 2011